Among the 14,737 patients who were recruited in the three included studies, randomization to SGLT2 inhibitor was associated with a 30% odds reduction in hospitalization for HF (OR: 0.70, 95%CI: 0.64–0.76), without any interaction with BMI (test for subgroup differences: x2 = 0.86, p = 0.83, and after inverse-variance weighted regression analysis p = 0.23). The gene discussed is SLC5A2; the disease is hydrops fetalis.